Der Onkologe

, Volume 13, Issue 11, pp 1029–1044 | Cite as

Maligne Keimzelltumoren des Hodens

Frühe Stadien
CME Weiterbildung • Zertifizierte Fortbildung
First Online:

Zusammenfassung

Die konsequente Orientierung am Prinzip der Interdisziplinarität führte zu beachtlichen Fortschritten in der Diagnostik und Therapie des malignen testikulären Keimzelltumors. Aus methodisch hochwertigen aktuellen Therapiestudien dieses Tumors wurden Bewertungen von Diagnostik, Behandlungsmodalitäten und Empfehlungen abgeleitet. Als deren Folge ist eine an der jeweiligen Befundkonstellation und Prognose ausgerichtete, stadien- und vom histologischen Subtyp abhängige Individualisierung der Therapie möglich. Sie erfolgt interdisziplinär multimodal nach jeweils definierten Algorithmen als systematische operative, radioonkologische und systemische zytostatische integrierte Behandlung. Es werden die von der European Germ Cell Cancer Consensus Group (EGCCCG) evidenzbasierten Aktualisierungen der Leitlinien zur Behandlung dieser Tumoren erläutert. Ihre zunehmende Beachtung und Umsetzung in der täglichen Praxis führte zu einem Absinken der Exzessmortalität beim Hodentumor und darf als Erfolg dieser europäischen interdisziplinären Kooperation bewertet werden.

Schlüsselwörter

Testikuläres Keimzellmalignom Seminom Nichtseminom Evidenzbasierte Medizin Stadien- und risikoadaptierte Therapie 

Malignant testicular germ cell tumors

Early stages

Abstract

The consistent orientation to the principle of the interdisciplinary approach has led to considerable progress in the diagnosis and therapy of malignant testicular germ cell tumors. Assessments of the diagnostics, treatment modalities and recommendations have been derived from methodical high-quality current clinical trials of this tumor. As a consequence, an patient-specific therapy is possible based on the individual constellation of findings and prognosis and dependent on the histological subtype. This is carried out in an interdisciplinary and multimodal manner according to defined algorithms as a systematic operative, integrated radiooncologic and systemic antineoplastic treatment. The updated evidence-based guidelines of the European Germ Cell Cancer Consensus Group (EGCCCG) for treatment of this tumor will be presented. The increasing observance and implementation of these guidelines in the routine practice has led to a reduction in excess mortality due to testicular tumors and the success should be attributed to this European interdisciplinary cooperation.

Keywords

Testicular cancer  Seminoma  Non-seminoma  Evidence-based medicine  Stage and risk-adapted treatment 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Albers P, Siener R, Kliesch S et al. (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 21: 1505–1512PubMedCrossRefGoogle Scholar
  2. 2.
    Albers P, Albrecht W, Algaba F et al. (2005) Guidelines on testicular cancer. Eur Urol 48: 885–894PubMedCrossRefGoogle Scholar
  3. 3.
    Aparicio J, Garcia del Muro X, Maroto P et al. Spanish Germ Cell Cancer Cooperative Group (GG) (2003) Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14: 867–872PubMedCrossRefGoogle Scholar
  4. 4.
    Aparicio J, Germa JR, Del Muro XG et al. (2005) Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol 23: 8717–8723PubMedCrossRefGoogle Scholar
  5. 5.
    Arranz Arija JA, García del Muro X, Gumà J et al. (2001) E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. Ann Oncol 12: 487–491CrossRefGoogle Scholar
  6. 6.
    Bray F, Richiardi L, Ekbom A et al. (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118: 3099–3111PubMedCrossRefGoogle Scholar
  7. 7.
    Classen J, Schmidberger H, Meisner C et al. (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21: 1101–1106PubMedCrossRefGoogle Scholar
  8. 8.
    Classen J, Schmidberger H, Meisner C et al. (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German Testicular Cancer Study Group (GTCSG). Br J Cancer 90: 2305–2311PubMedGoogle Scholar
  9. 9.
    Collette L, Sylvester RJ, Stenning SP et al. (1999) Impact of the treating institution on survival of patients with „poor-prognosis“ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91: 839–846PubMedCrossRefGoogle Scholar
  10. 10.
    Dahl AA, Mykletun A, Fossa SD (2005) Quality of life in survivors of testicular cancer. Urol Oncol 23: 193–200PubMedGoogle Scholar
  11. 11.
    De Wit M, Hartmann M, Kotzerke J et al. (2005) German Multicenter PET Study Group 18F-FDG-PET in clinical stage I and II non-seminomatous germ cell tumors: first results of the German multicenter trial. J Clin Oncol [Suppl] 23: 4504Google Scholar
  12. 12.
    Dieckmann KP, Pichlmeier U (1997) The prevalence of familial testicular cancer. Cancer 80: 1954–1960PubMedCrossRefGoogle Scholar
  13. 13.
    Dieckmann KP, Brüggeboes B, Pichlmeier U et al. (2000) Adjuvant treatment of clinical stage I seminoma: is one single course of carboplatin sufficient? Urology 55: 102–106PubMedCrossRefGoogle Scholar
  14. 14.
    Eble JN, Sauter G, Epstein JI et al. (2004) Pathology and genetics. Tumours of the urinary system and male genital organs. WHO classification of tumours. IARC, LyonGoogle Scholar
  15. 15.
    Fossa SD, Horwich A, Russel JM et al. (1999) Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. J Clin Oncol 117: 1146–1154Google Scholar
  16. 16.
    Fritz A, Percy C, Jack A et al. (2000) International classification of diseases for oncology (ICD–O), 3rd edn. WHO, GenfGoogle Scholar
  17. 17.
    Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G et al. (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16: 863–868PubMedCrossRefGoogle Scholar
  18. 18.
    Huddart R, O’Doherty M, Padhani A et al. (2006) A prospective study of 18 FDG PET in the prediction of relapse in patients with high risk clinical stage I (CSI) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. J Clin Oncol [Suppl] 24: 4520Google Scholar
  19. 19.
    International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603Google Scholar
  20. 20.
    Jones WG, Fossa SD, Mead GM et al. (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23: 1200–1208PubMedCrossRefGoogle Scholar
  21. 21.
    Kliesch S (2003) Fertilität bei Patienten mit Hodentumorerkrankungen. Onkologe 9: 955–961CrossRefGoogle Scholar
  22. 22.
    Krege S, Kalund G, Otto T et al. (1997) Phase II study: adjuvant single agent carboplatin therapy for clinical stage I seminoma. Eur Urol 31: 405–407PubMedGoogle Scholar
  23. 23.
    Krege S, Souchon R, Schmoll HJ (2001) Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 40: 372–391PubMedCrossRefGoogle Scholar
  24. 24.
    Krege S, Boergermann C, Baschek R et al. (2006) Single-agent carboplatin for CS II-A/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 17: 276–280PubMedCrossRefGoogle Scholar
  25. 25.
    Krege S, Wittekind C, Souchon R et al. (2006) Der Hodentumor: gestern – heute – morgen. Urologe A 45 S4: 169–175CrossRefGoogle Scholar
  26. 26.
    Krege S, Beyer J, Souchon R et al. (2007) Update 2006/2007 of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG) 2006/2007. Eur Urol, acceptedGoogle Scholar
  27. 27.
    Mostofi FK, Sesterhenn IA (1998) Histological typing of testis tumours. WHO international histological classification of tumours, 2nd edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  28. 28.
    Nicolai N, Miceli R, Artusi R et al. (2007) A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171: 172–176CrossRefGoogle Scholar
  29. 29.
    Oliver T, Dieckmann K-P, Steiner H et al. (2005) Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma (abstract #4572). J Clin Oncol 23: 395Google Scholar
  30. 30.
    Oliver RT, Mason MD, Mead GM (2005) MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366: 293–300PubMedCrossRefGoogle Scholar
  31. 31.
    Patterson H, Norman AR, Mitra SS et al. (2001) Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 59: 5–11PubMedCrossRefGoogle Scholar
  32. 32.
    Rübben H (Hrsg) (2007) Uroonkologie, 4. Aufl. Springer, Berlin Heidelberg New York, S 521–609Google Scholar
  33. 33.
    Schmoll HJ, Weißbach L, Bamberg M (1998) Therapie des Hodentumors: das Zauberwort heißt Interdisziplinarität. Onkologe 6: 471–472CrossRefGoogle Scholar
  34. 34.
    Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377–1399PubMedCrossRefGoogle Scholar
  35. 35.
    Sobin LH, Wittekind Ch (eds.) (2002) UICC: TNM classification of malignant tumours, 6th edn. Wiley-Liss, New YorkGoogle Scholar
  36. 36.
    Souchon R, Schmoll H-J, Krege S (Hrsg) (2002) Deutsche Krebsgesellschaft e.V. Qualitätssicherung in der Onkologie – Leitlinie zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin (EBM). Zuckschwerdt, MünchenGoogle Scholar
  37. 37.
    Travis LB, Fossa SD, Schonfeld SJ et al. (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97: 1354–1365PubMedCrossRefGoogle Scholar
  38. 38.
    Warde P, Specht L, Horwich A et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance. J Clin Oncol 20: 4448–4452PubMedCrossRefGoogle Scholar
  39. 39.
    Winstanley AM, Mikuz G, Debruyne F et al. (2004) Handling and reporting of biopsy and surgical specimens of testicular cancer. Eur Urol 45: 564–573PubMedCrossRefGoogle Scholar
  40. 40.
    Wittekind Ch, Loy V (2003) Pathomorphologische Diagnostik von Hodentumoren. In: Berufsverband Deutscher Pathologen und Deutsche Gesellschaft für Pathologie (Hrsg) Leitlinien des Berufsverbandes. Berufsverband Deutscher Pathologen und Deutsche Gesellschaft für Pathologie, GelsenkirchenGoogle Scholar
  41. 41.
    Zagars GK, Ballo MT, Lee AK et al. (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640–647PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Klinik für Strahlentherapie und RadioonkologieAllgemeines Krankenhaus Hagen gGmbH, Lehrstuhl für Radiologie und Mikrotherapie, Universität Witten/HerdeckeHagenDeutschland
  2. 2.Klinik für Strahlentherapie und Radiologische OnkologieSt. Vincentius-Kliniken KarlsruheKarlsruheDeutschland

Personalised recommendations